Sol-Gel Technologies Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults

Reuters09-04

<a href="https://laohu8.com/S/SLGL">Sol-Gel Technologies</a> Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults

Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003223), on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564376156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564376156","market":"nz","top_or_hot":-1,"title":"Sol-Gel Technologies Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLGL\">Sol-Gel Technologies</a> Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003223), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sol-Gel Technologies Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSol-Gel Technologies Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLGL\">Sol-Gel Technologies</a> Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003223), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLGL","symbol_name":"Sol-Gel Technologies","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL5fLzPk:1","article_id":"2564376156","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564376156","pubTimestamp":1756983768,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inves","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SLGL":"Sol-Gel Technologies"},"translate_title":"Sol-Gel Technologies Ltd.获得加拿大卫生部批准EPSOLAY治疗成人酒渣鼻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLGL":0.9},"content_text":"Sol-Gel Technologies Ltd. Secures Health Canada Approval for EPSOLAY to Treat Rosacea in Adults\n    \n\n        Sol-Gel Technologies Ltd. has announced that Health Canada has granted regulatory approval for EPSOLAY®, a treatment for inflammatory lesions of rosacea in adults. This approval was secured through Sol-Gel's partnership with Searchlight Pharma, which holds exclusive licensing rights for the commercialization of EPSOLAY in Canada. The Notice of Compliance was issued on August 27, 2025, enabling the launch of this innovative treatment for rosacea patients in the Canadian market. The approval is part of a broader strategy by Sol-Gel to commercialize EPSOLAY and TWYNEO across various global territories, with anticipated launches in Europe, Asia, Africa, Latin America, and Australia expected to begin in 2027 and 2028.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sol Gel Technologies Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003223), on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564376156","isCrawlerRequest":true}